Roche Holdings Ltd ADR (RHHBY)

$45.30 +0.60 (1.34%)
Market Cap 288.25B
Revenue (ttm) 70.87B
Net Income (ttm) 9.40B
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 15.32
Profit Margin 13.27%
Debt to Equity Ratio 0.96
Volume 1,475,300
Avg Vol 1,396,648
Day's Range N/A - N/A
Shares Out 6.36B
Stochastic %K 97%
Beta 0.47
Analysts Hold
Price Target $43.62

Company Profile

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19,...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 41 61 688 88 80
Fax: 41 61 691 00 14
Address:
Grenzacherstrasse 124, Basel, Switzerland
simplifocused
simplifocused Oct. 5 at 1:46 AM
$LMDX What rate is the payment likely? $RHHBY OR ROCHE ROG Rate? Which, and what rates? I am curious and eager to know NFA
1 · Reply
vincent_2025
vincent_2025 Oct. 4 at 7:06 PM
$RHHBY $TTOO Any interest in Roche and T2 Biosystems merger?
0 · Reply
Power2k
Power2k Oct. 3 at 1:24 PM
$VKTX The 3.5B takeover deal between $RHHBY and $ETNB took almost 3 yrs to mature, the Viking deal may even take much longer (4-5 yrs) considering a much higher TAM of the Obesity space, and we're a 3Billion company already. BL and the board members are working their butts off talking with multiple potential suitors and due diligences are conveyed between both parities almost on a daily basis. So let's be patient as the team is trying their best to get the company and us shareholders the deal as best as possible.
2 · Reply
Power2k
Power2k Oct. 3 at 12:44 PM
$AKRO $ETNB "On January 27, 2025, Akero Therapeutics, Inc. reported positive clinical trial results from a Phase 2b clinical trial in patients with compensated cirrhosis (fibrosis stage F4) due to MASH, which contributed to heightened industry focus on the FGF21 class of therapeutics and the fibrosis stage F4 segment. Shortly thereafter, representatives of Parent conveyed that Akero Therapeutics, Inc.’s data were a positive indicator for the class and that Parent wished to assemble a cross-functional team to engage in diligence with the intent of exploring a potential collaboration with 89bio." Are those Parties terminated talks with 89bio are in talks with Akero now? Man, we can't be just a "positive indicator", we are a major player in the MASH field. $VKTX $RHHBY https://www.fiercebiotech.com/biotech/after-courting-14-pharmas-89bio-was-left-between-roche-and-hard-place-buyout-talks
0 · Reply
Okadarlan
Okadarlan Oct. 2 at 11:19 PM
$RHHBY sale again here, i wont miss it if i was u !
0 · Reply
ImYourPhuckleberry
ImYourPhuckleberry Oct. 2 at 5:01 PM
$LMDX $RHHBY $FCN Law firm handling cases such as this has been contacted. Didn't want to pay us fair value? Fine. Now we'll take fair value PLUS damages.
1 · Reply
Gps_100X_ROI_Potential
Gps_100X_ROI_Potential Oct. 1 at 6:45 PM
$SLS $215M Mcap. up from 39 to 140 Institutional Funds Invested, since the IDMC Unblinded Actual Phase 3 Trial Data. - Gps is 100% for Sure Getting FDA Approval, and the whole market is about to Realize SLS is worth close to $20B to Big Pharma. Gps is getting the FDA Green light to treat upwards of 25,000 AML Remission Patients Each Year . . . all these short knuckle dragging scumbags @New_to_stock @MRTunity scraping for pennies are going to get Split Quartered, and served up with hot load of jerk sauce on their backs. ANY DAY NOW. $ABBV $BMY $RHHBY
0 · Reply
Gps_100X_ROI_Potential
Gps_100X_ROI_Potential Oct. 1 at 6:04 PM
$SLS MCAP $222M Up from $77M when the IDMC Unblinded Actual Phase 3 MOS and IR Interim Analysis data. The IDMC Unblinded Actual Median Overall Survival and Immune Response Trial Data from the Ongoing Phase 3 trial, that lets anyone paying attention, Know Gps is Golden. The IDMC stated Gps "exceeded predetermined futility criteria" ... and the 'ALL Pooled MOS' was not yet met, and already 13.5 months - We can know from this information, Control ARM MOS is Capped at Some number of Months Less than 13. Now 10 months since the IA, we Also know GPS P3 MOS is Absolutely Greater than the P2 MOS of 21 months. dd/ do some research. Gps is 100% for Sure Getting Fda Approval - That is why Angie is so Pumped. - shares are cheap. Also, $ABBV $BMY $RHHBY Know exactly how their drugs (aza Ven) perform in the CR2 setting.
0 · Reply
DavidT305
DavidT305 Sep. 30 at 1:10 PM
$ALT $RHHBY how is it highly differentiated when both lly liver trials have better data and more weight loss? That’s an interesting rationale
2 · Reply
BiotechBonesaw
BiotechBonesaw Sep. 30 at 12:44 PM
$ALT piper sandler maintained their $25 PT on AltImmune and things pemvi is better than 89bio’s asset that $RHHBY just bought for $3.5B GLB ☘️ 🐂
0 · Reply
Latest News on RHHBY
No data available.
simplifocused
simplifocused Oct. 5 at 1:46 AM
$LMDX What rate is the payment likely? $RHHBY OR ROCHE ROG Rate? Which, and what rates? I am curious and eager to know NFA
1 · Reply
vincent_2025
vincent_2025 Oct. 4 at 7:06 PM
$RHHBY $TTOO Any interest in Roche and T2 Biosystems merger?
0 · Reply
Power2k
Power2k Oct. 3 at 1:24 PM
$VKTX The 3.5B takeover deal between $RHHBY and $ETNB took almost 3 yrs to mature, the Viking deal may even take much longer (4-5 yrs) considering a much higher TAM of the Obesity space, and we're a 3Billion company already. BL and the board members are working their butts off talking with multiple potential suitors and due diligences are conveyed between both parities almost on a daily basis. So let's be patient as the team is trying their best to get the company and us shareholders the deal as best as possible.
2 · Reply
Power2k
Power2k Oct. 3 at 12:44 PM
$AKRO $ETNB "On January 27, 2025, Akero Therapeutics, Inc. reported positive clinical trial results from a Phase 2b clinical trial in patients with compensated cirrhosis (fibrosis stage F4) due to MASH, which contributed to heightened industry focus on the FGF21 class of therapeutics and the fibrosis stage F4 segment. Shortly thereafter, representatives of Parent conveyed that Akero Therapeutics, Inc.’s data were a positive indicator for the class and that Parent wished to assemble a cross-functional team to engage in diligence with the intent of exploring a potential collaboration with 89bio." Are those Parties terminated talks with 89bio are in talks with Akero now? Man, we can't be just a "positive indicator", we are a major player in the MASH field. $VKTX $RHHBY https://www.fiercebiotech.com/biotech/after-courting-14-pharmas-89bio-was-left-between-roche-and-hard-place-buyout-talks
0 · Reply
Okadarlan
Okadarlan Oct. 2 at 11:19 PM
$RHHBY sale again here, i wont miss it if i was u !
0 · Reply
ImYourPhuckleberry
ImYourPhuckleberry Oct. 2 at 5:01 PM
$LMDX $RHHBY $FCN Law firm handling cases such as this has been contacted. Didn't want to pay us fair value? Fine. Now we'll take fair value PLUS damages.
1 · Reply
Gps_100X_ROI_Potential
Gps_100X_ROI_Potential Oct. 1 at 6:45 PM
$SLS $215M Mcap. up from 39 to 140 Institutional Funds Invested, since the IDMC Unblinded Actual Phase 3 Trial Data. - Gps is 100% for Sure Getting FDA Approval, and the whole market is about to Realize SLS is worth close to $20B to Big Pharma. Gps is getting the FDA Green light to treat upwards of 25,000 AML Remission Patients Each Year . . . all these short knuckle dragging scumbags @New_to_stock @MRTunity scraping for pennies are going to get Split Quartered, and served up with hot load of jerk sauce on their backs. ANY DAY NOW. $ABBV $BMY $RHHBY
0 · Reply
Gps_100X_ROI_Potential
Gps_100X_ROI_Potential Oct. 1 at 6:04 PM
$SLS MCAP $222M Up from $77M when the IDMC Unblinded Actual Phase 3 MOS and IR Interim Analysis data. The IDMC Unblinded Actual Median Overall Survival and Immune Response Trial Data from the Ongoing Phase 3 trial, that lets anyone paying attention, Know Gps is Golden. The IDMC stated Gps "exceeded predetermined futility criteria" ... and the 'ALL Pooled MOS' was not yet met, and already 13.5 months - We can know from this information, Control ARM MOS is Capped at Some number of Months Less than 13. Now 10 months since the IA, we Also know GPS P3 MOS is Absolutely Greater than the P2 MOS of 21 months. dd/ do some research. Gps is 100% for Sure Getting Fda Approval - That is why Angie is so Pumped. - shares are cheap. Also, $ABBV $BMY $RHHBY Know exactly how their drugs (aza Ven) perform in the CR2 setting.
0 · Reply
DavidT305
DavidT305 Sep. 30 at 1:10 PM
$ALT $RHHBY how is it highly differentiated when both lly liver trials have better data and more weight loss? That’s an interesting rationale
2 · Reply
BiotechBonesaw
BiotechBonesaw Sep. 30 at 12:44 PM
$ALT piper sandler maintained their $25 PT on AltImmune and things pemvi is better than 89bio’s asset that $RHHBY just bought for $3.5B GLB ☘️ 🐂
0 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Sep. 29 at 11:26 PM
$LMDX $RHHBY
1 · Reply
ern1in
ern1in Sep. 27 at 2:04 AM
$TGTX $RHHBY
0 · Reply
dogDazeSummer
dogDazeSummer Sep. 26 at 11:47 PM
$IFRX Friendly reminder of Inflarx patent obtained in conjunction with Roche’s tocilizumab. Tocilizumab, originally approved as Actemra, has received FDA approval for various autoimmune and inflammatory conditions, including rheumatoid arthritis, polyarticular juvenile idiopathic arthritis. It is also approved for giant cell arteritis (GCA), COVID-19 in hospitalized patients. Ask yourself why Inflarx would obtain a patent for combined treatment of vilo + tocil—-and also if they wld do this—-> without first collaborating/ obtaining green light from $RHHBY $XBI $BBC
4 · Reply
Fingerlickengood
Fingerlickengood Sep. 26 at 7:39 PM
$CDXS $ALNY $RHHBY https://x.com/CMichaelGibson/status/1968762452213985413
0 · Reply
imatisse
imatisse Sep. 26 at 4:31 PM
$LCTX ❤️ $RHHBY With Lineage, the makers of Opregen, you buy the future of science!
0 · Reply
imatisse
imatisse Sep. 26 at 1:32 PM
$RHHBY ❤️$LCTX https://stocktwits.com/z06forum/message/630103816
0 · Reply
DonCorleone77
DonCorleone77 Sep. 26 at 2:50 AM
$AZN $GSK $NVS $RHHBY $BMY Trump to impose 100% tariff on drugs unless manufacturer building U.S. plant In a post on Truth Social, President Trump stated the following: "Starting October 1st, 2025, we will be imposing a 100% Tariff on any branded or patented Pharmaceutical Product, unless a Company IS BUILDING their Pharmaceutical Manufacturing Plant in America. "IS BUILDING" will be defined as, "breaking ground" and/or "under construction." There will, therefore, be no Tariff on these Pharmaceutical Products if construction has started. Thank you for your attention to this matter!"
2 · Reply
gatekeeper1
gatekeeper1 Sep. 25 at 10:09 PM
$RHHBY $TGTX @ians @Quad_ @PotionX1900 @Rickerthestockpicker1 @stu @RonIsWrong @Cozman @Taylonious @WirthM13 @steven1x @no1chode @Pennzwoods @mTOR
2 · Reply
ern1in
ern1in Sep. 25 at 3:19 PM
$TGTX $RHHBY
2 · Reply
imatisse
imatisse Sep. 25 at 7:43 AM
$RHHBY Dear Roche friends… At the beginning, when Roche launched its investment in Lineage’s Opregen, we were quite suspicious… now the process is going very smoothly and Lineage is exploring new horizons.
0 · Reply
Quantumup
Quantumup Sep. 23 at 7:04 PM
Baird reiterated $LCTX at Outperform-$5 and said that it is Incrementally Positive On $LCTX Following Partner $RHHBY's R&D Day, Where The SVP Of Ophthalmology Went So Far As To State That OpRegen Was A "personal favorite." Here is what Baird had to say: Lineage partner Roche (RHHBY, not covered) held an R&D day yesterday, and we remain encouraged by management's comments/posture surrounding the OpRegen program. Roche included multiple slides on OpRegen, and the SVP of ophthalmology went so far as to state that OpRegen was a "personal favorite" during his prepared remarks. Signals such as these reinforce our belief that Roche remains committed to the program (especially in the context on an ongoing open-label Phase 2 study). In the image below is what I posted in the past on X from B.Riley:
1 · Reply
imatisse
imatisse Sep. 23 at 3:29 PM
$LCTX ❤️ Opregen /ROCHE - $RHHBY Attention Roche and Genentech Boy’s and Girls! - $RHHBY Attenzione ragazzi e ragazze Roche e Genentech! - $RHHBY Attention Roche et Genentech garçons et filles !
0 · Reply